HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
NATIONAL CANCER INSTITUTE
· United States · $6.21M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.